Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...

Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...

For 2025, Waters expects constant currency sales growth of 4.5%-7%, translating to total reported sales growth of approximately 2.5%-5% due to FX headwinds. Non-GAAP EPS guidance is projected at ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

Investing.com - CVS Health has posted better-than-anticipated income and revenue in the fourth quarter, as the healthcare group pursues a broad overhaul of its operations under new Chief Executive ...

T-knife Therapeutics, Inc., a biopharmaceutical company developing T cell receptor (TCR) engineered T cell therapies (TCR-T) to fight cancer, today announced that members of the company’s management ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Biohaven Ltd. (BHVN – ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners ...

In a challenging market environment, LAVA Therapeutics NV (LVTX) stock has recorded a new 52-week low, dipping to $0.88. With a market capitalization of $23.8 million, the company maintains a strong ...